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Background: The health benefits of soy are widely reported but there are queries on the
effect of soy isoflavones on thyroid function and the underlying mechanism of action.
Materials and Methods: We examined the effect of soy isoflavones on reverse
tri-iodothyronine (or 3,3′,5′-tri-iodothyronine; rT3) in two studies comprising 400 patients:
200 men (study 1; 3 months) and 200 post-menopausal women (study 2; 6 months) who
were randomized to consume 15g soy protein with 66mg of isoflavones (SPI) daily, or
15 g soy protein alone without isoflavones (SP) daily.
Results: SPI supplementation increased rT3 serum concentration in both men 0.41
(0.12) vs. 0.45 (0.14) nmol/L and women 0.33 (0.12) vs. 0.37 (0.09) nmol/L at 3 months
compared to SP that was not seen at 6 months. Thyroid stimulating hormone (TSH)
serum concentrations increased while free thyroxine (fT4) concentrations decreased with
3 months of SPI compared to SP supplementation for both men and women. rT3
correlated with TSH in both studies (p = 0.03) but not with either fT3 or fT4. fT3 levels
did not differ between the SPI and SP preparations.
Conclusion: Soy isoflavones transiently increased rT3 levels within 3 months though
reverted to baseline at 6 months. The mechanism for this would be either rT3 degrading
deiodinase 1 and/or deiodinase 2 activities are transiently inhibited at 3 months, or
inhibition of deiodinase 3, which generates rT3 from T4 is induced at 6 months. These
changes were mirrored in the TSH concentrations, suggesting that short-term high dose
isoflavone transiently impairs thyroid function in the first 3 months and may impact on
general health during this period.
ISRCTN Registry: ISRCTN 90604927; ISRCTN34051237.
Keywords: soy, isoflavones, phytoestrogens, reverse tri-iodothyronine, tri-iodothyronine, thyroxine, TSH
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INTRODUCTION
The consumption of soy food products have increased due to the
reported potential health benefits that have been suggested to be
due to the isoflavone components, leading to the development
of isoflavone supplements and the fortification of foods with
isoflavones (1, 2). It has been suggested that the soy isoflavones
might provide protection against breast and prostate cancer (3–
5), osteoporosis (6), cardiovascular diseases (7, 8) and alleviate
hot flashes (9). However, there are concerns in susceptible
individuals that soy may adversely affect thyroid function (10–
14). The mechanism by which soy isoflavones may interfere
with thyroid function is unclear, but it is critical to understand
given the wide spread use of soy products. Animal studies
have suggested that soy isoflavones interfere with thyroid
function via thyroid peroxidase inhibition, as well as, with tissue
deiodinase enzyme activities, which may affect extrathyroidal
thyroid hormone metabolism, including rT3 concentrations (15).
Isoflavones might also displace thyroid hormones from their
distributor proteins in the blood (16).
We have shown that high dose isoflavone intake, in
comparison with isoflavone free soy, impair thyroid function in
patients with type 2 diabetes (T2DM) (Study 1) (17) and also in
post-menopausal healthy women (Study 2) (18). Study 1 was a
randomized double-blind parallel study investigating the effect
of soy isoflavones on testosterone serum concentrations in men
with T2DM; 3 months of high dose isoflavone intake resulted
in a significant increase in serum concentrations of thyrotropin
(TSH) and a reduction of free thyroxine (fT4) with no changes
in serum free tri-iodothyronine (fT3) concentration. Similarly, in
study 2, a double-blind randomized parallel study investigating
the effect of high dose isoflavone intake on bone turnover
markers in women within 2 years of onset of menopause, 6
months of high dose isoflavone resulted in a significant increase
in TSH and reduction of fT4 with no changes in fT3. As
rT3 is a major endogenous T4 metabolite, probably devoid of
major biological action in adults, we analyzed potential rT3
concentration changes in serum, which might be harbingers of
altered thyroid hormone distribution and metabolism (19). We
conducted this post-hoc analysis to understand the impact of high
dose isoflavones on rT3 concentrations and their correlation with
other thyroid measurement parameters tests including fT3, fT4
and TSH.
RESEARCH DESIGN AND METHODS
Study 1 involved 200 men aged between 45 and 75 years with
T2DM, low earlymorning total testosterone concentrations (total
testosterone less than the lower level of the reference range of
12 nmol/L) and normal gonadotropins who participated in a
randomized double blind parallel study investigating the effect of
soy isoflavones on serum testosterone concentrations (17). They
were randomized either to intake of 15 g soy protein with 66mg
of isoflavones (SPI) per day or 15 g soy protein alone without
any isoflavones (SP) per day for 3 months in the form of snack
bars (Figure 1A). Study 2 involved 200 healthy women within
2 years of the onset of their menopause who were recruited
(20) to assess the impact of high dose soy isoflavones on bone
turnover markers. They were randomized into either the SPI
group (15 g soy protein with 66mg of isoflavones) or SP group
(15 g soy protein alone, isoflavone free) daily intake for a period of
6months in the form of snack bars (Figure 1B). Thyroid function
tests including fT3, fT4, and TSH were secondary outcomes for
both studies.
Participants were required to avoid food products containing
soy, alcohol, mineral, or vitamin supplementation. All patients
were euthyroid and none of the patients were on thyroxine
supplementation or on medications, which are known to
affect thyroid function. The snack bars were consumed
twice daily between meals. Dietary reinforcement together
with measurement of plasma isoflavone concentrations was
undertaken at each visit to ensure adherence. All subjects
gave their written informed consent. Both studies received
ethical approval by the Research Ethics Committee (East
Yorkshire & North Lincolnshire Research Ethics Committee,
ref: 09/H1304/45 and 09/1304/45). Computer-generated block
randomization list was performed by Essential Nutrition Ltd.,
Brough, UK, who held the randomization codes for both the
studies.
TSH, fT3, and fT4 assays were performed on an Abbott
Architect i4000 immunoassay analyser (Abbott Diagnostics
Division, UK) as batched samples. Analytical performance in
terms of imprecision at discreet levels (% CV, Mean) for fT4
was 4%, 13.7 pmol/L, for fT3 was 11.2%, 0.33 nmol/L, and that
of TSH was 4.2%, 1.32 mU/L. The rT3 concentrations were
measured in duplicate by competitive radioimmunoassay (total
rT3 RIA, lot R-EW-125-1614A; Radim Deutschland GmbH,
Freiburg, Germany) according to the manufacturer’s instructions
as a batched analysis. The assay range was 0.04–3.10 nmol/L and
inter-assay %CV was <11.2%. The isoflavones were extracted
and analyzed from serum by LGC, Fordham, Cambridgeshire,
UK using isotope-dilution LC-MS/MS (21). LC-MS/MS was
conducted using a Sciex4000Qtrap with separation achieved
using a C18 column and mobile phases of acetonitrile and water,
both containing acetic acid (17).
Study Product
“The intervention consisted of a snack bar containing 7.5 g
isolated soy protein powder (Solcon F, Solbar Industries, Israel)
with 33mg of isoflavones (SPI) (Solgen 40, Solbar Industries,
Israel) given twice daily between meals (15 g soy protein and
66mg of isoflavones per day), or 7.5 g of the isolated soy
protein given twice daily (15 g soy protein per day without
isoflavones per day) as control (SP). The latter had an
isoflavone concentration of <300 parts per billion following
serial alcohol extraction by Dishman Ltd., India (20); and
product isoflavones assayed by FERA, Sand Hutton, UK (20).
Analysis showed the composition of the dose materials to be
12% glycitein, 35% daidzein, and 54% genistein as aglycones.
90% of isoflavones were in the primary glucoside form, with the
remaining 10% as aglycones as malonyl and acetyl glucosides.
The snack bars were consumed twice daily between meals
for 6 months. The study bars were prepared and packaged
by Halo foods, Swindon, UK.” Soy bars were identical and
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FIGURE 1 | Flow diagrams detailing the participants through studies 1 and 2 from recruitment to the end of the studies. (A) Flow diagram of participants through the
study 1. (B) Flow diagram of participants through the study 2.
had similar macronutrient content and a tasting panel had
determined that there was no discernible difference between the
2 products.
Statistical Analysis
This is a post-hoc exploratory analysis of two studies to
understand the impact of high dose isoflavones on rT3
concentrations and their correlation with other serum thyroid
hormone measurement parameters tests including fT3, fT4, and
TSH hence apriori power calculation was not done for changes in
rT3.
Baseline continuously distributed data is presented as median
(25/75th centiles); categorical data by n (%). Within-group
differences (difference between 12 weeks/24 weeks values and
baseline values) are shown for each treatment group separately
by a mean and a standard deviation (SD). Between-group
comparisons were performed using the independent sample t-
test. The t-test assumes equal variance between groups. Changes
of rT3 concentrations (1rT3) with each supplementation was
correlated with changes in fT3 (1fT3), changes in fT4 (1fT4)
and changes in TSH (1TSH) by Spearman correlation coefficient
method. For all statistical analyses, a two-tailed P < 0.05
was considered to indicate statistical significance. Statistical
analysis was performed using the STATA statistical computer
package (StataCorp 2013. Stata Statistical Software: StataCorp LP,
USA).
RESULTS
In Study 1, there was a significant increase in rT3 with SPI
supplementation [0.41 (0.12) vs. 0.45 (0.14) nmol/L] at 3 months
compared to SP supplementation [0.43 (0.10) vs. 0.40 (0.15)
p-value < 0.001] (Tables 1, 2) in men with type 2 diabetes.
SPI supplementation increased TSH within 3 months [Mean
(SD)] [1.81 (0.92) vs. 3.23 (1.03) mU/L] compared to SP
supplementation [1.82 (0.93) vs. 1.96 (1.11) mU/L]. Conversely,
SPI supplementation decreased free T4 within 3 months [12.68
(1.90) vs. 11.09 (2.00) pmol/L] compared to SP supplementation
[13.06 (1.74) vs. 12.74 (1.62) pmol/L]. There were no changes
in fT3 with 3 months of either SPI or SP supplementation.
There was a significant correlation between changes in rT3 with
TSH (r = 0.52; p = 0.03) but no correlation with changes
in fT3 (r = 18; p = 0.81) and fT4 (r = 13; p = 0.62
0.81).
In Study 2 in healthy women within 2 years of menopause
(Table 3), SPI supplementation increased rT3 [0.33 (0.12) vs. 0.37
(0.09) nmol/L] compared to SP supplementation (p < 0.001)
within 3 months. The rT3 decreased after 6 months 0.31 (0.13)
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TABLE 1 | Changes in reverse T3 at 3 months for study 1 and at 3 and 6 months for study 2.
Changes in reverse T3 (rT3)
Baseline 3 months p-value (baseline vs. 3
months between groups)
6 months p-value (baseline vs. 6
months between groups)
p-value (3 vs. 6 months
between groups)
STUDY 1
SPI 0.41 (0.12) 0.45 (0.14) <0.001
SP 0.43 (0.10) 0.40 (0.15)
STUDY 2
SPI 0.33 (0.12) 0.37 (0.09) <0.001 0.31 (0.13) 0.81 0.001
SP 0.33 (0.11) 0.33 (0.12) 0.30 (0.12)
SPI, 15 g soy protein with 66mg of isoflavones; SP, 15 g soy protein alone isoflavone free. Results in Mean (SD).
TABLE 2 | Baseline characteristics of study 1 participants.




Body mass index (kg/m2) 31.6 (29.2, 35.0) 31.8 (28.8, 34.7)
Age (years) 52.0 (50.0, 55.0) 52.0 (50.0, 55.0)
HbA1c (mmol/mol) 58 (53, 64) 56 (52, 60)
Duration of diabetes (years) 7.9 (4.4, 9.1) 7.3 (4.2, 8.8)
HbA1c (mmol/mol) 58 (53, 64) 56 (52, 60)
fT4 (pmol/L) 13.0 (12.0, 14.0) 12.0 (12.0, 14.0)
fT3 (pmol/L) 4.6 (4.2, 4.9) 4.6 (4.2, 5.0)
TSH (mU/L) 1.6 (1.2, 2.5) 1.6 (1.2, 2.4)
Data are provided as medians (25/75th centiles).
fT4, free thyroxine; fT3, free tri-iodo thyronine; TSH, thyroid stimulating hormone.
TABLE 3 | Baseline characteristics of study 2 participants.




Body mass index (kg/m2) 24.6 (22.7, 28.4) 26.3 (24.3, 30.7)
Age (years) 52 (50, 55) 52 (49, 56)
fT4 (pmol/L) 13 (12, 14) 13 (13, 15)
fT3 (pmol/L) 4.7 (4.3, 4.9) 4.6 (4.3, 5.1)
TSH (mU/L) 1.6 (0.9, 2.3) 1.5 (0.9, 2.2)
Data are provided as medians (25/75th centiles). fT4, free thyroxine; fT3, free tri-iodo
thyronine; TSH, thyroid stimulating hormone.
of SPI supplementation and was comparable to baseline (p-value
= 0.81). Mean TSH increased significantly [mean (SD) 1.58
(0.93) vs. 2.61 (1.24) mU/L, p < 0.01] with a corresponding
reduction in mean fT4 [13.5 (2.2) vs. 11.2 (1.8) pmol/L, p < 0.01]
from baseline to 3 months. There was a significant correlation
between changes in rT3 with TSH (r = 0.612; p = 0.02) but no
correlation with changes in fT3 (r = 22; p-value = 0.42) or fT4
(r = 18; p-value = 0.38) at 3 months. There was no correlation
between changes in rT3 with changes in TSH, fT4 and fT3 at
6 months.
There were no changes in TSH and fT4 between 3 and 6
months. There were no differences in the fT3 between both
preparations.
DISCUSSION
There was a significant increase in rT3 in both studies after 3
months of high dose isoflavone supplementation, whereas the
rT3 values did not differ in isoflavone-free soy, suggesting that
it is the isoflavone component that is responsible for the rT3
changes seen. However, in the study 2 involving post-menopausal
women the rT3 decreased to baseline values after 6 months
of SPI supplementation, suggesting that the isoflavone induced
changes are transient and return to normal pretreatment thyroid
homeostasis over a 6-months period.
In both studies, there was a reduction in fT4 and a
corresponding rise in TSH, suggesting that the feedback
response of the hypothalamo-pituitary-thyroid axis was intact.
In situations where the thyroid cannot maintain thyroid
hormone production, either due to an autoimmune process
and/or lack of the essential trace element iodine, there would
be a shift in thyroidal production from a 20:1 T4:T3 ratio
to a ratio more in favor of T3. A preferential production
and secretion of T3 compared to T4 could potentially explain
why there were no significant changes in fT3 despite changes
in TSH and fT4. Dose and duration of SPI consumption
might not yet be sufficient to also decrease serum fT3
considering that the majority of T3 is generated outside
of the thyroid gland by Type 1 and Type II 5′-deiodinase
activities. Furthermore, SPI isoflavones might enhance (hepatic
and/or gastrointestinal) T4 elimination by hepatic enzyme
induction, as frequently observed for drugs (e.g., phenobarbital)
and xenobiotics, while serum T3 concentration are still
maintained (22–24). However, given the uniform response of
the increase in rT3 in response to high dose isoflavones,
this would suggest that this change is not idiosyncratic.
Interestingly, changes in serum rT3 in the SPI isoflavone
consuming groups were similar in T2DM male patients and
post-menopausal women, which in our opinion would exclude
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effects solely restricted to T2DM patients or post-menopausal
women.
Serum T4 is metabolized either to the active thyroid hormone
T3 or to the inactive rT3 in a reciprocal manner depending upon
the relative actions of the tissue deiodinase enzymes types 1 to
3. The mechanism of the increase in rT3 seen in both studies
is unclear. One of the main sources of rT3 is the peripheral
conversion of thyroxine to rT3. The enzyme responsible for
this is deiodinase type 3 and it could be hypothesized that
isoflavones may activate deiodinase type 3 (25), but no data
has been reported on direct stimulation of expression of any
of the deiodinases by isoflavones. Degradation of rT3 is mainly
accomplished by hepatic and renal deiodinase type 1, but also by
deiodinase type 2 (25). Therefore, another plausible explanation
would be that isoflavones (transiently) inhibit hepatic deiodinase
1 (and/or extrahepatic deiodinase 2) (25), which would lead
to accumulation of rT3 in blood. However, in rat-studies we
have shown that deiodinase type 1 activity in the liver is
increased after 16 weeks of isoflavone treatment (15), which
might be due to higher hepatic uptake and exposure to
thyroid hormone which may be displaced by flavonoids from
its binding to transthyretin (16, 26). Administration of high
concentrations of rT3, administered in rodent experiments, did
not affect serum TSH and thyroid hormones, albeit type 2
deiodinase activity was inhibited and hepatic gene expression
was affected (27) The short half-life and rapid turnover of rT3
might result in these transient changes and flavonoid effects on
deiodinase isoenzymes and transthyretin might mainly manifest
as variations in rT3 serum concentrations which is only weakly
bound to serum distribution proteins compared to T4 and
T3. Whether the thyroid itself is also affected by isoflavones
and/or responds to altered TSH concentration, which might
induce activity and expression of type 1 and type 2 deiodinases
and thus maintain T3 concentration, requires detailed kinetic
studies (28). There may be multiple mechanisms through which
isoflavones act on thyroid hormone metabolism, distribution
and/or transport systems with a complexity that needs further
elucidation. It is also unknown if the isoflavone effects would be
different between patients with and without autoimmune thyroid
disease.
Reduced circulating levels of fT3 are a sensitive marker
of ill health especially in context of elevated rT3 (29). In a
population of elderly men, who were independently living, serum
rT3 concentrations increased with age and the presence of
comorbidities (29). Higher serum rT3 concentrations may result
from decreased peripheral metabolism of TH due to the aging
process itself and/or disease and may reflect a catabolic state
(29). Indeed, fasting, cold exposure, and even minor infective
or inflammatory disease are sufficient to reduce serum fT3 and
elevate rT3 concentrations in otherwise-healthy individuals (30,
31).
In a cohort of elderly people, baseline serum rT3
concentration was associated with all-cause mortality during
a 9-years period of follow up, suggesting that rT3 may be a
more sensitive marker for non-thyroidal illness than fT3 (32).
No significant mortality associations were found with serum
fT3, fT4 or TSH concentrations. However, in men lower serum
TSH, and in women higher rT3 concentrations, predicted
disability (32). These findings broadly confirm those of previous
studied cohorts of older people (33, 34), and are in line with the
known pathophysiological mechanisms whereby low fT3 and
higher rT3 concentrations are non-specifically associated with
increasing ill health and disease burden (31). In the elderly, high
rT3 is a stronger predictor of all-cause mortality than low fT3
independent of disease burden (32).
Dietary intake of isoflavones in Asian soy diets has been
estimated to be in the range of 30–50mg per day of combined
isoflavone aglycone equivalents (35, 36). In Western countries
an average daily intake of ∼2mg isoflavones is seen though
estimated to be 16mg in vegetarians (37); therefore, the
dose of 66mg of isoflavones used in this study may be
considered to be in the pharmacological range for this study
purpose.
In conclusion, these studies show that the isoflavone
component of soy protein transiently increases rT3
concentrations when supplemented over a period of 3 months
but afterwards rT3 concentrations reverted to baseline at 6
months, perhaps due to deiodinase 3 inhibition. These changes
were mirrored in the TSH values, suggesting that high dose
isoflavones may transiently impair thyroid homeostasis, though
it is not clear if this would impact clinically on general health.
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